Credit Suisse’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $265M | Sell |
4,884,813
-1,793,918
| -27% | -$91.4M | 0.25% | 68 |
|
|
2023
Q4 | $343M | Buy |
6,678,731
+510,808
| +8% | +$26.8M | 0.33% | 53 |
|
|
2023
Q3 | $358M | Buy |
6,167,923
+341,884
| +6% | +$20.9M | 0.36% | 46 |
|
|
2023
Q2 | $373M | Buy |
5,826,039
+261,652
| +5% | +$17.5M | 0.37% | 40 |
|
|
2023
Q1 | $386M | Buy |
5,564,387
+162,687
| +3% | +$11.5M | 0.39% | 41 |
|
|
2022
Q4 | $389M | Buy |
5,401,700
+581,111
| +12% | +$43.8M | 0.41% | 39 |
|
|
2022
Q3 | $343M | Buy |
4,820,589
+128,943
| +3% | +$9.35M | 0.38% | 43 |
|
|
2022
Q2 | $361M | Buy |
4,691,646
+395,009
| +9% | +$30.1M | 0.38% | 47 |
|
|
2022
Q1 | $314M | Buy |
4,296,637
+218,972
| +5% | +$14.7M | 0.27% | 65 |
|
|
2021
Q4 | $254M | Sell |
4,077,665
-24,437
| -0.6% | -$1.43M | 0.14% | 132 |
|
|
2021
Q3 | $243M | Sell |
4,102,102
-253,890
| -6% | -$16.7M | 0.13% | 139 |
|
|
2021
Q2 | $289M | Sell |
4,355,992
-238,150
| -5% | -$15.5M | 0.15% | 121 |
|
|
2021
Q1 | $290M | Sell |
4,594,142
-219,402
| -5% | -$13.7M | 0.15% | 122 |
|
|
2020
Q4 | $299M | Sell |
4,813,544
-462,329
| -9% | -$28.4M | 0.15% | 133 |
|
|
2020
Q3 | $318M | Buy |
5,275,873
+255,156
| +5% | +$15.4M | 0.19% | 94 |
|
|
2020
Q2 | $295M | Sell |
5,020,717
-1,352,157
| -21% | -$80.9M | 0.21% | 90 |
|
|
2020
Q1 | $355M | Sell |
6,372,874
-4,401,812
| -41% | -$269M | 0.31% | 53 |
|
|
2019
Q4 | $692M | Buy |
10,774,686
+261,309
| +2% | +$15M | 0.5% | 25 |
|
|
2019
Q3 | $533M | Sell |
10,513,377
-1,372,851
| -12% | -$64.5M | 0.45% | 32 |
|
|
2019
Q2 | $539M | Buy |
11,886,228
+8,281,100
| +230% | +$386M | 0.48% | 25 |
|
|
2019
Q1 | $172M | Sell |
3,605,128
-3,298,923
| -48% | -$164M | 0.16% | 111 |
|
|
2018
Q4 | $359M | Buy |
6,904,051
+3,765,188
| +120% | +$202M | 0.37% | 49 |
|
|
2018
Q3 | $195M | Sell |
3,138,863
-65,862
| -2% | -$3.91M | 0.17% | 92 |
|
|
2018
Q2 | $177M | Buy |
3,204,725
+55,841
| +2% | +$3.02M | 0.17% | 97 |
|
|
2018
Q1 | $199M | Sell |
3,148,884
-822,852
| -21% | -$52.9M | 0.19% | 93 |
|
|
2017
Q4 | $243M | Buy |
3,971,736
+75,055
| +2% | +$4.69M | 0.22% | 82 |
|
|
2017
Q3 | $248M | Sell |
3,896,681
-62,801
| -2% | -$3.67M | 0.24% | 73 |
|
|
2017
Q2 | $225M | Sell |
3,959,482
-2,350,861
| -37% | -$128M | 0.22% | 82 |
|
|
2017
Q1 | $343M | Buy |
6,310,343
+231,892
| +4% | +$12.7M | 0.31% | 54 |
|
|
2016
Q4 | $355M | Buy |
6,078,451
+2,522,674
| +71% | +$138M | 0.35% | 48 |
|
|
2016
Q3 | $192M | Buy |
3,555,777
+605,102
| +21% | +$38.9M | 0.18% | 94 |
|
|
2016
Q2 | $217M | Buy |
2,950,675
+85,878
| +3% | +$6.07M | 0.24% | 75 |
|
|
2016
Q1 | $183M | Sell |
2,864,797
-189,918
| -6% | -$12M | 0.22% | 89 |
|
|
2015
Q4 | $210M | Sell |
3,054,715
-615,129
| -17% | -$40.6M | 0.24% | 80 |
|
|
2015
Q3 | $217M | Sell |
3,669,844
-3,496,931
| -49% | -$222M | 0.26% | 76 |
|
|
2015
Q2 | $477M | Buy |
7,166,775
+1,417,907
| +25% | +$93.4M | 0.46% | 27 |
|
|
2015
Q1 | $371M | Buy |
5,748,868
+1,304,751
| +29% | +$81.7M | 0.37% | 43 |
|
|
2014
Q4 | $262M | Buy |
4,444,117
+658,041
| +17% | +$37.1M | 0.23% | 82 |
|
|
2014
Q3 | $194M | Buy |
3,786,076
+203,863
| +6% | +$10.2M | 0.16% | 114 |
|
|
2014
Q2 | $174M | Sell |
3,582,213
-352,729
| -9% | -$17.4M | 0.14% | 135 |
|
|
2014
Q1 | $204M | Buy |
3,934,942
+386,045
| +11% | +$20.5M | 0.2% | 91 |
|
|
2013
Q4 | $189M | Sell |
3,548,897
-479,429
| -12% | -$24.4M | 0.17% | 101 |
|
|
2013
Q3 | $186M | Sell |
4,028,326
-1,027,227
| -20% | -$45.1M | 0.19% | 93 |
|
|
2013
Q2 | $226M | Buy |
+5,055,553
| New | +$219M | 0.23% | 70 |
|
Other funds holding BMY
Credit Suisse's BMY Position: Q1 2024 in Review
Credit Suisse reduced its Bristol-Myers Squibb (BMY) stake by 27% in Q1 2024, selling an estimated $91.4M and leaving 4,884,813 shares worth $265M. The position accounts for 0.25% of the portfolio, ranked #68.
Credit Suisse first reported a position in BMY in Q2 2013 and has held it in 44 quarters since. The position peaked at $692M in Q4 2019. 2,331 funds tracked by Wall St. Rank hold BMY as of Q1 2024.
- Credit Suisse held 4,884,813 shares of Bristol-Myers Squibb worth $265M as of Q1 2024.
- Credit Suisse sold 1,793,918 Bristol-Myers Squibb shares in Q1 2024, an estimated $91.4M.
- Bristol-Myers Squibb made up 0.25% of Credit Suisse's portfolio in Q1 2024, its #68 holding.
- Credit Suisse first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Bristol-Myers Squibb position peaked at $692M in Q4 2019.
- 2,331 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.